WHO Raises Doubts About India’s Wyeth Pneumonia Vaccinations
This article was originally published in PharmAsia News
The pneumococcal conjugate vaccine India decided recently to add to its national immunization program apparently has no effect on the disease, according to the World Health Organization. A WHO bulletin said the PCV not only does not fight pneumonia, it actually increases asthma risks in children. A high-level committee of experts in India's Health Ministry earlier recommended including PCV in the immunization program and the ministry said it would do so within a year despite its high cost of more than $90 per child. The WHO bulletin advised governments to assess the cost of the Wyeth drug given its questionable effect, but Wyeth said the bulletin item contained inaccuracies and misleading statements. (Click here for more
You may also be interested in...
The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”
Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.
COVID-19 Consumer Health Market: Germ-Blocking Nasal Spray, 99.99% Effective Sanitizer, ‘Mask’ To Moisturize Hands
Sensory Cloud’s small study showed FEND nasal solution cut by 99% exhalation of bioaerosol to block COVID-19. Global BioProtect’s hand sanitizer with proprietary antibacterial technology eliminates 45 bacteria, fungi and virus. Trilogy Labs’ solution replenishes moisture in hands irritated by sanitizers.